KURA
Price
$6.71
Change
+$0.15 (+2.28%)
Updated
Jun 6, 10:44 AM (EDT)
Capitalization
568.8M
55 days until earnings call
ZYME
Price
$12.45
Change
+$0.31 (+2.56%)
Updated
Jun 6, 11:35 AM (EDT)
Capitalization
845.26M
Interact to see
Advertisement

KURA vs ZYME

Header iconKURA vs ZYME Comparison
Open Charts KURA vs ZYMEBanner chart's image
Kura Oncology
Price$6.71
Change+$0.15 (+2.28%)
Volume$800
Capitalization568.8M
Zymeworks
Price$12.45
Change+$0.31 (+2.56%)
Volume$242
Capitalization845.26M
KURA vs ZYME Comparison Chart
Loading...
KURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KURA vs. ZYME commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KURA is a Buy and ZYME is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (KURA: $6.57 vs. ZYME: $12.13)
Brand notoriety: KURA and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KURA: 62% vs. ZYME: 45%
Market capitalization -- KURA: $568.8M vs. ZYME: $845.26M
KURA [@Biotechnology] is valued at $568.8M. ZYME’s [@Biotechnology] market capitalization is $845.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KURA’s FA Score shows that 1 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • KURA’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than KURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KURA’s TA Score shows that 5 TA indicator(s) are bullish while ZYME’s TA Score has 6 bullish TA indicator(s).

  • KURA’s TA Score: 5 bullish, 3 bearish.
  • ZYME’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, ZYME is a better buy in the short-term than KURA.

Price Growth

KURA (@Biotechnology) experienced а +12.89% price change this week, while ZYME (@Biotechnology) price change was +6.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.36%. For the same industry, the average monthly price growth was +17.11%, and the average quarterly price growth was +3.22%.

Reported Earning Dates

KURA is expected to report earnings on Jul 31, 2025.

ZYME is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+11.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZYME($845M) has a higher market cap than KURA($569M). ZYME YTD gains are higher at: -17.145 vs. KURA (-24.569). ZYME has higher annual earnings (EBITDA): -110.05M vs. KURA (-177.18M). KURA has more cash in the bank: 658M vs. ZYME (265M). ZYME (18.5M) and KURA (19.4M) have identical debt. ZYME has higher revenues than KURA: ZYME (93.4M) vs KURA (68M).
KURAZYMEKURA / ZYME
Capitalization569M845M67%
EBITDA-177.18M-110.05M161%
Gain YTD-24.569-17.145143%
P/E RatioN/AN/A-
Revenue68M93.4M73%
Total Cash658M265M248%
Total Debt19.4M18.5M105%
FUNDAMENTALS RATINGS
KURA vs ZYME: Fundamental Ratings
KURA
ZYME
OUTLOOK RATING
1..100
1112
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9291
PRICE GROWTH RATING
1..100
8855
P/E GROWTH RATING
1..100
10066
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KURA's Valuation (27) in the Biotechnology industry is in the same range as ZYME (45) in the Pharmaceuticals Major industry. This means that KURA’s stock grew similarly to ZYME’s over the last 12 months.

KURA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ZYME (100) in the Pharmaceuticals Major industry. This means that KURA’s stock grew similarly to ZYME’s over the last 12 months.

ZYME's SMR Rating (91) in the Pharmaceuticals Major industry is in the same range as KURA (92) in the Biotechnology industry. This means that ZYME’s stock grew similarly to KURA’s over the last 12 months.

ZYME's Price Growth Rating (55) in the Pharmaceuticals Major industry is somewhat better than the same rating for KURA (88) in the Biotechnology industry. This means that ZYME’s stock grew somewhat faster than KURA’s over the last 12 months.

ZYME's P/E Growth Rating (66) in the Pharmaceuticals Major industry is somewhat better than the same rating for KURA (100) in the Biotechnology industry. This means that ZYME’s stock grew somewhat faster than KURA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KURAZYME
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
85%
Bearish Trend 16 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
63%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
KURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LDFVX15.33N/A
N/A
Lord Abbett Fundamental Equity A
AMTZX9.45N/A
N/A
AB All Market Real Return Z
PJFPX71.00N/A
N/A
PGIM Jennison Growth R4
MXMSX10.48N/A
N/A
Empower Small Cap Growth Instl
LZCOX9.36-0.04
-0.43%
Lazard US Small Cap Equity Select Open

KURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KURA has been loosely correlated with PYXS. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if KURA jumps, then PYXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KURA
1D Price
Change %
KURA100%
+1.86%
PYXS - KURA
65%
Loosely correlated
-3.52%
ZYME - KURA
44%
Loosely correlated
-0.57%
KYMR - KURA
44%
Loosely correlated
+7.68%
ADVM - KURA
44%
Loosely correlated
-1.82%
AXON - KURA
41%
Loosely correlated
+1.08%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with ABCL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
-0.57%
ABCL - ZYME
48%
Loosely correlated
-2.27%
LENZ - ZYME
48%
Loosely correlated
+3.80%
NRIX - ZYME
46%
Loosely correlated
+2.80%
BEAM - ZYME
45%
Loosely correlated
-0.87%
ABEO - ZYME
45%
Loosely correlated
+0.62%
More